MedWaves, Inc. Sponsors Investigational Studies to Evaluate Its Patented Microwave Thermal Coagulation-Ablation System for Treatment of Tumors in Liver and Lung
SAN DIEGO, Sept. 18 /PRNewswire/ — MedWaves, Inc. announces ongoing investigational studies to determine the effectiveness of its microwave ablation system for treating soft tissue lesions, such as tumors, in liver and lung. The studies using MedWaves’ AveCure(TM) microwave coagulation-ablation system, which includes a generator and probe/antenna (FDA 510(k) cleared and CE Mark certified), are showing promising results.
The AveCure(TM) system, which includes a microwave generator and sterile single-patient-use probes, enables the surgeons and interventional radiologists to safely treat soft tissue problems, such as tumors in the liver and lung, using thermal coagulation-ablation. AveCure(TM) system uses temperature and power feedback from the antenna and nearby tissue to intelligently control microwave power to the ablation zone. The changes in temperature and power absorption are indicative of thermal tissue destruction brought on by microwave energy absorbed in the ablation zone. By utilizing and displaying dynamic changes in temperature and power, MedWaves’ AveCure(TM) system safely and efficiently ablates small or large zones using far less power than other ablation systems in the market. The same feedbacks are available for the user to manage the ablation process with confidence. Therefore, MedWaves’ is inherently safer, does not require irrigation cooling, and less likely to cause collateral damage as with other systems currently in the market.
Images 1A and 1B show a lung tumor (54mm x 62mm x 62mm) ablation zone created with a single AveCure(TM) probe. The physician’s comment was, “… I have never seen this size (large) of an ablation zone with a single microwave antenna…”
Images 1A and 1B: http://www.ereleases.com/pr/2009-MedWaves-Image-1A-and-1B.jpg
Multiple AveCure(TM) systems can concurrently apply energy to treat larger lesions or shape the ablation zone to fit lesion boundaries. Image-2 below shows a liver lesion (70mm x 70mm x 90mm) ablation zone created by using three AveCure(TM) probes. The top left image is pre-ablation; top center and top right images are during ablation; bottom three images are post-ablation.
Image 2: http://www.ereleases.com/pr/2009-MedWaves-Image-2.jpg
PDF File of Release with Images: http://www.ereleases.com/pr/2009-MedWaves-News-Release.pdf
Post-ablation images show significant shrinkage in the liver tissue ablation zone. The AveCure(TM) probe of the same type percutaneously ablated a kidney cyst as well. MedWaves’ proprietary microwave technology delivers predictable ablation performance not seen in other microwave and radiofrequency systems in the market, and shows its versatility. Additional benefits of microwave ablation are less pain and discomfort during percutaneous outpatient procedures, and clinical cases have shown to significantly reduce anesthetic dosage requirements when compared to radiofrequency ablation. The reduced anesthetic requirement could allow the physicians to treat larger populations of patients. Innovation continues at MedWaves. The company is developing smaller diameter microwave probes/antennae with focused microwave fields to destroy small metastatic lesions in liver, lung and other organs safely and effectively.
The energy-based therapy generates sales of $25 billion worldwide and growing at 11% per annum. Current worldwide tumor ablation generates sales of $250 million and growing at 25%-30% per annum. This accounts for only 5% market penetrated by market leaders such as Covidien, AngioDynamics, Boston Scientific, Medtronic, and Ethicon. The overall market potential for tumor ablation therapy is estimated at $5 billion and expected to grow 50% by 2015.
About The AveCure(TM) Ablation System and Devices
MedWaves’ microwave coagulation-ablation system overcomes limitations of existing microwave and radiofrequency (RF) thermal ablation technologies, the standard treatment for cancerous tumor patients who are not candidates for resection surgery. For these patients, microwave thermal ablation therapy can be either adjuvant or replacement therapy for the standard curative and/or palliative treatments, e.g. chemotherapy and/or radiation. It is an option for patients where other thermal modalities are not possible due to tumor size or location. The real-time temperature and power monitoring of MedWaves AveCure(TM) microwave coagulation-ablation system are unique features, not available in other systems, which provide physicians with information necessary to treat patients safely, effectively and confidently.
About MedWaves, Inc.
MedWaves, Inc. develops innovative and proprietary microwave ablation technology for minimally invasive and surgical coagulation-ablation therapy of soft tissues and tumors. The Company’s management team has extensive experience in the medical device marketplace. MedWaves’ clinical advisors include renowned interventional radiologists and surgeons from UCSD, St. Joseph, The Cushier Skills Center, Brown University, and University of Pisa. MedWaves, Inc. is a privately held corporation located in San Diego, California, USA.
FDA has not cleared AveCure(TM) microwave coagulation-ablation system for the specific treatment of liver or lung cancers.
Contact Information: Ted Ormsby, President/CEO 16760 W Bernardo Drive San Diego, CA 92127 Tel: 858-946-0015 Fax: 858-946-0016 Email: email@example.com Website: http://www.medwaves.com
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
SOURCE MedWaves, Inc.